For instance, one approach is the inhibition of NLRP3 inflammasome by fenamate, a class of nonsteroidal anti-inflammatory drugs that by attenuating microglia activation reduces the cognitive deficits in two rodent models of AD in vivo (Daniels et al., 2016). This evidence concerns the gene NLRP3 and Alzheimer disease.